Molly Harper has extensive experience in all phases of pre-launch market development and global biopharmaceutical commercial operations, and leads Akcea’s global expansion strategies. Ms. Harper joined Akcea in April 2015 and serves as Vice President, Global Head and General Manager in the TTR and Cardiometabolic Franchises. She is responsible for all aspects of the volanesorsen business in addition to the commercialization strategy for Akcea’s cardiometabolic pipeline programs. She came to Akcea from the Rare Disease division of Genzyme, where she was Senior Director and Head of US Endocrinology. In her role, she was responsible for all commercial functions for several development programs and products, as well as management of a molecular diagnostic co-promotion program with Veracyte, Inc. Her earlier roles at Genzyme included Global and U.S. Marketing leads for the Endocrine and Cardiovascular businesses. Prior to Genzyme, Ms. Harper was with Merck & Co., where she held positions in the Atherosclerosis and Acute Care franchises across marketing management, market research, and sales. She has also held positions in life sciences equity research at UBS Warburg and strategy consulting with The Wilkerson Group/IBM. Ms. Harper has an MBA from The Wharton School of the University of Pennsylvania and she is a past board member of The Wharton Health Care Management Alumni Association and current board member of The Wharton Club of Boston. She also holds a BA from Cornell University.